Breaking News Instant updates and real-time market news.

TMUS

T-Mobile

$78.05

1.18 (1.54%)

, S

Sprint

$5.83

-0.03 (-0.51%)

09:10
11/18/19
11/18
09:10
11/18/19
09:10

Fly Intel: Pre-market Movers

HIGHER: Qiagen (QGEN), up 3% after announcing late on Friday that the company is exploring potential strategic alternatives following "several conditional, non-binding indications of interest"... NIO Inc, (NIO), up 4% after appointing Wei Feng as CFO... Teekay Tankers (TNK), up 3% after BofA Merrill Lynch analyst Ken Hoexter issued a double-upgrade on shares to Buy from Underperform with a price target of $3, up from $2... Karuna Therapeutics (KRTX), up 72% after KarXT met its primary endpoint in a Phase 2 trial... Yandex (YNDX) up 6% after announcing a $300M share repurchase program. DOWN AFTER EARNINGS: Quidian (QD), down 8%. ALSO LOWER: T-Mobile US (TMUS), down 2% after announcing that Mike Sievert, who is currently President, COO and a director, will assume the CEO role from John Legere after the conclusion of Legere's contract on April 30, 2020... SunPower (SPWR), down 4% after filing to sell 22M shares of common stock... Xerox (XRX) and HP Inc, (HPQ), down 2% and 1%, respectively, after HP announced that its board has unanimously rejected the unsolicited acquisition proposal from Xerox... Ultra Clean (UCTT), down 2% after Stifel analyst Patrick Ho downgraded the stock to Hold from Buy with an unchanged price target of $21. The analyst says the downgrade is "based entirely on valuation".

TMUS

T-Mobile

$78.05

1.18 (1.54%)

S

Sprint

$5.83

-0.03 (-0.51%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

NIO

NIO Inc.

$1.82

0.07 (4.01%)

TNK

Teekay Tankers

$2.39

0.155 (6.94%)

KRTX

Karuna Therapeutics

$17.26

-0.26 (-1.48%)

YNDX

Yandex

$35.74

1.19 (3.44%)

QD

Qudian

$7.49

-0.115 (-1.51%)

SPWR

SunPower

$8.29

0.3 (3.75%)

XRX

Xerox

$38.95

0.295 (0.76%)

HPQ

HP Inc.

$20.17

0.05 (0.25%)

UCTT

Ultra Clean

$22.62

-0.01 (-0.04%)

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 26

    Nov

  • 07

    Dec

  • 09

    Dec

TMUS T-Mobile
$78.05

1.18 (1.54%)

11/04/19
RAJA
11/04/19
UPGRADE
Target $49
RAJA
Strong Buy
U.S. Cellular upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Ric Prentiss upgraded U.S. Cellular to Strong Buy from Outperform with a price target of $49, down from $53, following what he calls an overreaction on Friday to the Q3 results. In a research note to investors, Prentiss says he believes the brand refresh and new rate plans will continue to drive foot traffic into stores, helping postpaid phone subscriber growth and continues to believe the best option to maximize return on invested capital for U.S. Cellular would be to affiliate with, or sell to, a larger carrier, whether the T-Mobile (TMUS)-Sprint (S) merger is approved or not. The analyst views shares as "very attractive."
11/14/19
HSBC
11/14/19
DOWNGRADE
HSBC
HSBC downgrades AT&T, Verizon, T-Mobile and Altice USA to Hold
HSBC analyst Sunil Rajgopal downgraded to Hold from Buy shares of AT&T (T), Verizon Communications (VZ), T-Mobile (TMUS) and Altice USA (ATUS). The analyst's only Buy in US Telecoms is now Comcast (CMCSA). Rajgopal keeps Reduce ratings on both Dish (DISH) and Sprint (S). The "evolving content business model" and increasing competition leads the analyst to be more cautious on the pay-TV business and operators with greater exposure to content revenues. Producers are increasingly distributing their content directly to consumers rather than relying on the cable and satellite aggregators, Rajgopal tells investors in a research note. In addition, the entry of a "well-funded" companies like Apple (AAPL) into content production and distribution "with its low sticker price adds to the concerns," contends the analyst. Rajgopal cut his pay-TV subscriber estimates for Comcast, AT&T, Charter and Altice USA to reflect his more cautious stance. The analyst lowered his price target for Altice USA to $28 from $30, raised his price target for AT&T to $42 from $38, raised his price target for Verizon to $65 from $62, and kept an $86 price target on T-Mobile.
11/14/19
HSBC
11/14/19
DOWNGRADE
Target $86
HSBC
Hold
T-Mobile downgraded to Hold from Buy at HSBC
HSBC analyst Sunil Rajgopal downgraded T-Mobile to Hold from Buy with an $86 price target.
11/14/19
11/14/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Sell from Hold at Maxim with analyst Nehal Chokshi saying his survey data lead him to project iPhone revenue in fiscal Q2 that is 14% below consensus iPhone revenue that is 6% below consensus for fiscal year 2020. He also expects operating profit to decline year-over-year due to his below consensus iPhone view. 2. Kraft Heinz (KHC) downgraded to Sell from Neutral at Goldman Sachs with analyst Jason English saying shares are up 15% since the company reported Q3 results on October 31. 3. Verizon (VZ), AT&T (T), and T-Mobile (TMUS) downgraded to Hold from Buy at HSBC. 4. Myomo (MYO) downgraded to Neutral from Buy at Roth Capital with analyst Scott Henry saying he sees lowered future expectations for the company after its Q3 results missed expectations. 5. Albemarle (ALB) downgraded to Neutral from Buy at Seaport Global with analyst Michael Harrison saying "challenging" lithium market dynamics are now anticipated to continue though 2020. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
S Sprint
$5.83

-0.03 (-0.51%)

11/01/19
COWN
11/01/19
NO CHANGE
Target $260
COWN
Outperform
American Tower price target raised to $260 from $238 at Cowen
Cowen analyst Colby Synesael raised his price target on American Tower (AMT) to $260 from $238 following in-line Q3 results. The analyst said the recent India situation as well as the pending T-Mobile (TMUS)/Sprint (S) merger creates near-term uncertainty but he views the recent selloff as a buying opportunity. He expects more meaningful upside in 2020 when the India and merger situations are resolved. Synesael maintained his Outperform rating on American Tower shares.
10/29/19
RHCO
10/29/19
NO CHANGE
Target $95
RHCO
Buy
T-Mobile price target raised to $95 from $80 at SunTrust
SunTrust analyst Greg Miller raised his price target on T-Mobile (TMUS) to $95 and kept his Buy rating, saying the company's Q3 results continue to "demonstrate strength" of its "UnCarrier strategy" and its ability to capture market share in a more "competitive and mature" market place. The analyst further states that he remains optimistic that the company's can close its Sprint (S) merger with only an approval by federal regulators and contends that T-Mobile remains among "best" in the space.
QGEN Qiagen
$40.56

3.255 (8.73%)

11/14/19
STFL
11/14/19
INITIATION
Target $33
STFL
Hold
Qiagen initiated with a Hold at Stifel
Stifel analyst Daniel Arias initiated coverage of Qiagen with a Hold rating and $33 price target. The analyst sees "substantial risk" given the nascency of the company's key products and markets being targeted. Further, he sees consensus estimates for 2020 as too high, and has a lack confidence in the ability to reach the company's "not-yet-withdrawn" mid-term growth target.
11/14/19
EVER
11/14/19
UPGRADE
Target $42
EVER
Outperform
Evercore upgrades Qiagen to Outperform after report of Thermo Fisher interest
Evercore ISI analyst Luke Sergott upgraded Qiagen (QGEN) to Outperform from In Line with a price target of $42, up from $31, following a Bloomberg report yesterday that Thermo Fisher (TMO) may be considering a buyout of the company. He thinks Qiagen business is "attractive" within the Tools landscape and he believes the company's operations have been appropriately reset following two quarters of misses and the CEO transition, Sergott tells investors. He also sees the possibility for acceleration given the incremental growth he expects from new products, the analyst added.
11/18/19
CCMC
11/18/19
UPGRADE
Target $48
CCMC
Buy
Qiagen upgraded to Buy from Hold at Commerzbank
Commerzbank analyst Daniel Wendorff upgraded Qiagen to Buy from Hold with a $48 price target.
11/15/19
JPMS
11/15/19
NO CHANGE
Target $330
JPMS
Overweight
JPMorgan sees Qiagen shares worth $43 in potential Thermo Fisher deal
JPMorgan analyst Tycho Peterson says historical comps and synergy opportunities imply a takeover price for Qiagen (QGEN) of $43 per share in a deal with Thermo Fisher (TMO). The analyst assumes Thermo would fund the reported acquisition with a mix of cash on hand and new debt. He sees potential for 75c-80c earnings per share accretion in year one, $1.06-$1.09 accretion in year two, and $1.53 accretion in year five. Further, Peterson feels the antitrust risk of a deal is manageable. He keeps an Overweight rating on Thermo Fisher with a $330 price target.
NIO NIO Inc.
$1.82

0.07 (4.01%)

10/04/19
GSCO
10/04/19
DOWNGRADE
GSCO
Neutral
NIO Inc. downgraded to Neutral from Buy at Goldman Sachs
09/26/19
WOLF
09/26/19
DOWNGRADE
Target $1.9
WOLF
Peer Perform
NIO Inc. downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research analyst Dan Galves downgraded NIO Inc. to Peer Perform from Outperform, stating that the company's cash burn was worse than expected in Q2 and its volume and margin guidance was "disappointing." The company's financing outlook has become "completely unclear" and the lack of a financing announcement along with earnings is "concerning," said the analyst, who set a $1.90 price target on the stock.
10/04/19
GSCO
10/04/19
DOWNGRADE
Target $1.47
GSCO
Neutral
Goldman Sachs downgrades NIO Inc. to Neutral, slashes target to $1.47 from $9.76
Goldman Sachs analyst Fei Fang downgraded NIO Inc. to Neutral from Buy with a price target of $1.47, down from $9.76. Nio's share price has fallen 40% since September 24, when the company announced Q2 results, which Fang attributes to uncertainties about volume since Chinese EV sales have rapidly declined after the government reduced electric vehicle subsidies and about the company's capital structure and funding needs. Fang maintains a 2023 estimate of the total addressable market for EVs in China of 1M new car sales, but lowered Nio's 2023 market share forecast to 15% from 25% due to more intense EV competition.
10/04/19
10/04/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. HP Inc. (HPQ) downgraded to Hold from Buy at Loop Capital with analyst Ananda Baruah citing HP's Analyst Day presentation disclosing strategic initiatives, job cuts, and a free cash flow guide of $3B in FY20 vs. $3.7B in FY21. 2. Insulet (PODD) downgraded to Neutral from Buy at UBS with analyst Matthew Taylor citing valuation. 3. NIO Inc. (NIO) downgraded to Neutral from Buy at Goldman Sachs with analyst Fei Fang saying Nio's share price has fallen 40% since September 24, when the company announced Q2 results, which Fang attributes to uncertainties about volume since Chinese EV sales have rapidly declined after the government reduced electric vehicle subsidies and about the company's capital structure and funding needs. 4. EchoStar (SATS) downgraded to Neutral from Buy at Citi with analyst Michael Rollins saying the company's lack of free cash flow and limited visibility on its future growth prospects will likely limit the potential for multiple expansion. 5. Ambarella (AMBA) resumed with a Hold from Buy at Stifel with analyst Tore Svanberg saying he believes inventory build in security surveillance, especially China, could limit near term upside in the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TNK Teekay Tankers
$2.39

0.155 (6.94%)

10/23/19
JEFF
10/23/19
UPGRADE
Target $2.5
JEFF
Buy
Jefferies upgrades Teekay Tankers to Buy, boosts target to $2.50 from $1.50
Jefferies analyst Randy Giveans upgraded Teekay Tankers to Buy from Hold with a price target of $2.50, up from $1.50. The analyst increased his price targets for all tanker companies saying asset values are starting to reflect the "massive increases" in charter rates. Teekay Tankers had the largest price target increase on a percentage basis. The analyst expects OPEC production surprises to the upside to cause crude oil tanker demand and correspondingly crude oil tanker charter rates and asset values to strengthen.
11/18/19
BOFA
11/18/19
UPGRADE
Target $3
BOFA
Buy
Teekay Tankers upgraded two notches to Buy from Underperform at BofA/Merrill
BofA/Merrill analyst Ken Hoexter issued a double-upgrade on Teekay Tankers to Buy from Underperform with a price target of $3, up from $2. Despite the 83% run-up in the stock price since October, the analyst contends that shares can "re-rate higher" with crude tanker markets current being in the "early stages of a robust recovery" and given the company's "attractive operating leverage" to rate inflections. Hoexter adds that Teekay's mid-sized vessels will also benefit from an improving crude tanker market, with the current tanker demand expected at 6% FY20 that should "materially outpace muted fleet supply growth of 1-2%."
11/18/19
BOFA
11/18/19
UPGRADE
BOFA
Buy
Teekay Tankers upgraded to Buy from Underperform at BofA/Merrill
BofA/Merrill upgraded Teekay Tankers to Buy from Underperform.
10/23/19
JEFF
10/23/19
UPGRADE
Target $2.5
JEFF
Buy
Teekay Tankers upgraded to Buy from Hold at Jefferies
Jefferies analyst Randy Giveans upgraded Teekay Tankers to Buy from Hold with a $2.50 price target.
KRTX Karuna Therapeutics
$17.26

-0.26 (-1.48%)

07/23/19
WELS
07/23/19
INITIATION
Target $29
WELS
Outperform
Karuna Therapeutics initiated with an Outperform at Wells Fargo
Wells Fargo analyst David Maris started Karuna Therapeutics with an Outperform rating and $29 price target. The company is addressing markets with significant unmet medical need and if approved, its lead product KarXT could have sales of $500M to $1B-plus, Maris tells investors in a research note.
07/23/19
SBSH
07/23/19
INITIATION
Target $28
SBSH
Buy
Karuna Therapeutics initiated with a Buy at Citi
Citi analyst Mohit Bansal started Karuna Therapeutics with a Buy rating and $28 price target. If successful, the company's xanomeline would offer a new mechanism of action versus current antipsychotics, and would be the first treatment targeting negative and cognitive symptoms, Bansal tells investors in a research note. He believes the Phase 2 schizophrenia data by year-end 2019 "will further de-risk the program" and sees the opportunity in that setting reaching $2B in sales.
07/23/19
WEDB
07/23/19
INITIATION
Target $38
WEDB
Outperform
Karuna Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst Liana Moussatos started coverage of Karuna Therapeutics with an Outperform rating and a $38 price target. The analyst considers Karuna Therapeutics to be an opportunity to invest in a breakthrough oral treatment for symptoms and cognitive impairment associated with schizophrenia and Alzheimer's disease as well as pain. Due to millions of schizophrenia and Alzheimer's disease patients and low compliance for current "dirty" drugs available for psychosis and nothing approved for negative symptoms or cognitive impairment, Moussatos sees blockbuster sales potential for KarXT. Starting with U.S. launch in 2023, she estimates KarXT could achieve over $1B in gross peak annual sales in 2027 and more than $4B in 2030.
07/23/19
GSCO
07/23/19
INITIATION
Target $34
GSCO
Buy
Karuna Therapeutics initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter started Karuna Therapeutics with a Buy rating and $34 price target. The analyst sees a favorable risk/reward setup since xanomeline has also demonstrated benefits in psychosis and cognition in two prior trials. He projects KarXT global peak sales of $4.4B.
YNDX Yandex
$35.74

1.19 (3.44%)

10/11/19
UBSW
10/11/19
NO CHANGE
Target $54.3
UBSW
Buy
Negative market reaction on Yandex 'overdone,' says UBS
UBS analyst Ulyana Lenvalskaya notes that Yandex is down nearly 16% on Friday following Thursday's discussion in Duma about potential implementation of the limit on foreign ownership to strategic internet businesses initially proposed in July. Lenvalskaya tells investors in a research note that the incremental negatives from Thursday's meeting look limited and she sees the extent of the negative market reaction as overdone. She maintains a Buy rating and $54.30 price target on Yandex shares.
10/14/19
BOFA
10/14/19
NO CHANGE
Target $50
BOFA
Buy
Foreign ownership limit worries create opportunity to buy Yandex, says BofA
BofA Merrill Lynch analyst Cesar Tiron noted that Yandex shares are down recently, which he thinks is mainly related to an article from suggesting that a bill that aims to limit foreign ownership limits for "important information sources" to 20% is supported by the Kremlin administration. He thinks FOL limits in the bill can be amended and remains optimistic on Yandex's compliance with such a law given there has been no mention that such a bill would apply to economic ownership and compliance would be possible with limited dilution through the creation of a new class of shares, Tiron tells investors. Calling the pullback a buying opportunity, he keeps a Buy rating and $50 price target on Yandex shares.
06/11/19
VTBC
06/11/19
UPGRADE
VTBC
Buy
Yandex upgraded to Buy from Hold at VTB Capital
06/27/19
OTRG
06/27/19
INITIATION
OTRG
Positive
Yandex initiated with a Positive at OTR Global
QD Qudian
$7.49

-0.115 (-1.51%)

05/14/19
CHRS
05/14/19
INITIATION
Target $8
CHRS
Hold
Qudian assumed with a Hold at China Renaissance
China Renaissance analyst Jiang Zhang assumed coverage of Qudian with a Hold rating and $8 price target, citing the company's uncertain long-term growth outlook.
05/01/19
DBAB
05/01/19
NO CHANGE
DBAB
LexinFintech, Qudian to benefit if China issues licenses, says Deutsche Bank
Deutsche Bank said that China's Banking and Insurance Regulatory Commission has announced its regulation drafting schedule for 2019, noting that the plan includes regulation intended for online micro lending businesses. The firm believes that getting a proper online lending license is a key upside event for listed online lenders in China, pointing to LexinFintech (LX) and Qudian (QD) as "key beneficiaries" in the event licenses get issued. The firm raised its price targets for both stocks as it factors in a 50% chance of obtaining an online lending license with lower cost of equity assumptions. Deutsche Bank maintains a Buy rating on LexinFintech and a Hold rating on Qudian.
04/08/19
MSCO
04/08/19
UPGRADE
Target $7.2
MSCO
Overweight
Morgan Stanley says Qudian 'attractive enough' to upgrade to Overweight
Morgan Stanley analyst John Cai said he views concerns about Qudian's regulatory and macro risks as overdone and believes the valuation of his top pick in online lending has become "attractive enough" to warrant an upgrade to Overweight from Equal Weight. Cai, who forecasts 2019 year-over-year net profit growth of 37% for Qudian, lowered his price target on the stock to $7.20 from $10.50.
10/10/19
BOCM
10/10/19
INITIATION
Target $6.82
BOCM
Neutral
Qudian initiated with a Neutral rating at BOCOM
BOCOM analyst Hannah Han initiated coverage of Qudian with a Neutral rating and $6.82 price target.
SPWR SunPower
$8.29

0.3 (3.75%)

08/01/19
FBCO
08/01/19
UPGRADE
FBCO
Outperform
SunPower upgraded to Outperform from Neutral at Credit Suisse
10/07/19
COWN
10/07/19
NO CHANGE
Target $83
COWN
Outperform
Tariff exemption positive for First Solar, says Cowen
Cowen analyst Jeffrey Osborne said the US Trade Representative pulled the tariff exemption for bifacial solar panels which were exempt from the current 25% tariff. The analyst said he expects a favorable reaction from First Solar (FSLR) shares and to a lesser extent SunPower (SPWR). He said the sharp increase in bifacial capacity coupled with a China slowdown has pressured the shares recently but this should provided some relief. Osborne maintained his Outperform rating and $83 price target on First Solar shares.
10/07/19
GSCO
10/07/19
NO CHANGE
GSCO
Goldman says U.S. solar makers should benefit from end of bifacial exemption
Goldman Sachs analyst Brian Lee noted that the Office of the United States Trade Representative said it will withdraw a previously granted Section 201 tariff exemption for bifacial solar panels, which he sees removing a key potential overhang for solar panel pricing and U.S. competition and also believes was unexpected by most investors. Lee thinks U.S. solar manufacturers such as First Solar (FSLR) and SunPower (SPWR) are key beneficiaries of the news, while Chinese solar panel makers with bifacial capacity expansion plans, including JinkoSolar (JKS) and Canadian Solar (CSIQ), are most likely to be negatively impacted. Lee has Buy ratings on First Solar, SunPower and Canadian Solar and a Sell rating on JinkoSolar.
10/30/19
CFRA
10/30/19
DOWNGRADE
CFRA
Hold
SunPower downgraded to Hold from Buy at CFRA
CFRA downgraded SunPower to Hold from Buy.
XRX Xerox
$38.95

0.295 (0.76%)

11/07/19
DBAB
11/07/19
NO CHANGE
DBAB
Hold
Xerox acquisition of HP 'improbable,' says Deutsche Bank
Deutsche Bank analyst Jeriel Ong sees a deal where Xerox (XRX) acquires HP Inc. (HOQ) as "improbable (but not financially impossible)" for the sole reason that Xerox is less than one-third the size of HP at the suggested $22-$23 per share offer. The analyst surmises that both companies are likely early in their discussions surrounding a potential deal. Ong has a Hold rating on HP shares. The analyst adds, however, that the deal appears to be "pretty accretive" to Xerox shareholders.
11/12/19
JPMS
11/12/19
UPGRADE
Target $38
JPMS
Neutral
JPMorgan upgrades Xerox to Neutral with shares close to fair value
JPMorgan analyst Paul Coster upgraded Xerox (XRX) to Neutral from Underweight with a price target of $38, up from $31. The analyst thinks the stock is trading close to fair value, but sees "catalysts to the upside and downside in the very near term." Xerox's bid for HP Inc. (HPQ) could conceivably lead HP to make a counter-bid for Xerox at a premium to where Xerox stock is currently trading, Coster tells investors in a research note. On the other hand, Xerox could successfully acquire HP and its stock could price in cost synergies, ahead of the deal closing, adds the analyst. However, looking further out, he believes Xerox's future "remains uncertain."
11/18/19
DBAB
11/18/19
NO CHANGE
DBAB
Hold
HP letter to Xerox indicates openness in combination, says Deutsche Bank
Deutsche Bank analyst Jeriel Ong says that while HP Inc.'s (HPQ) offer rejection reduces the odds of Xerox (XRX) being the acquirer, he believes the letter also communicates the openness HP has in evaluating a combination. It is unclear whether Xerox increasing the offer price would improve the odds of a combination as HPQ is already concerned about debt load at the $22 per share offer, Ong tells investors in a research note. The analyst continues to believe that a combination makes sense with HP as the acquirer rather than the target. He keeps a Hold rating on HP.
11/12/19
JPMS
11/12/19
UPGRADE
Target $38
JPMS
Neutral
Xerox upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Paul Coster upgraded Xerox to Neutral from Underweight with a $38 price target.
HPQ HP Inc.
$20.17

0.05 (0.25%)

11/11/19
EVER
11/11/19
UPGRADE
Target $24
EVER
Outperform
HP Inc. upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Amit Daryanani upgraded HP Inc. to Outperform from In Line with a $24 price target.
11/15/19
GDHS
11/15/19
NO CHANGE
GDHS
Gordon Haskett says Ackman, Icahn could be buyer behind Nomura's Netflix stake
Don Bilson, who heads Gordon Haskett's event-driven research team, said in a note prior to the open that Nomura's largest stock purchase last quarter was Netflix (NFLX), noting that the Japanese bank "put Mantle Ridge into Aramark (ARMK) and Carl Icahn into HP (HPQ) via a swap or some sort of options trade that remained on Nomura's books" previously. He speculated Bill Ackman could be the buyer behind Nomura's stakeholding, even "though there is nothing for an activist to do" at Netflix, given it fits the pattern of some other Pershing Square stock investments and Ackman mentioned not long ago that he had built a new, unnamed position. If it's not Ackman, "we suppose it could be Carl Icahn who just proved he knows who to call at Nomura" and his son, who previously got Icahn into the stock, is set to rejoin his fund shortly, Argenti wrote in his pre-open note.
UCTT Ultra Clean
$22.62

-0.01 (-0.04%)

10/24/19
CHLM
10/24/19
NO CHANGE
Target $22.5
CHLM
Buy
Ultra Clean price target raised to $22.50 from $16 at Craig-Hallum
Craig-Hallum analyst Christian Schwab raised his price target for Ultra Clean (UCTT) to $22.50 from $16 following Lam Research's (LRCX) "strong" results and raised outlook. The analyst reiterates a Buy rating on Ultra Clean's shares.
10/24/19
DADA
10/24/19
UPGRADE
Target $34
DADA
Buy
Ichor Holdings upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Thomas Diffely upgraded Ichor Holdings (ICHR) to Buy from Neutral with a price target of $34, up from $25. The analyst says that at 11-times his expected forward earnings, the stock is attractively priced relative to its closest peer Ultra Clean Holdings' (UCTT) 14-times multiple. Diffely is also positive on Ichor Holdings taking share from ASML Holding (ASML) and Appliet Materials (AMAT) with added strong leverage exposure to the "eventual memory recovery".
11/18/19
STFL
11/18/19
DOWNGRADE
Target $21
STFL
Hold
Ultra Clean downgraded to Hold from Buy at Stifel
Stifel analyst Patrick Ho downgraded Ultra Clean to Hold from Buy with an unchanged price target of $21. The analyst says the downgrade is "based entirely on valuation."
11/01/19
STPT
11/01/19
DOWNGRADE
STPT
Hold
Ultra Clean downgraded to Hold from Buy at Standpoint Research
Standpoint Research downgraded Ultra Clean to Hold from Buy.

TODAY'S FREE FLY STORIES

BCS

Barclays

$9.74

0.655 (7.21%)

, BP

BP

$36.95

-0.005 (-0.01%)

10:39
12/15/19
12/15
10:39
12/15/19
10:39
Recommendations
Barclays, BP, Amadeus IT Group, Anglo American, BT Group, Carlsberg, Demant, E.ON, Intertek, Novartis, Persimmon, Puma, RSA Insurance, Koninklijke Vopak, Hammerson, NMC Health, Reckitt Benckiser, Renault analyst commentary  »

Jefferies gives European…

BCS

Barclays

$9.74

0.655 (7.21%)

BP

BP

$36.95

-0.005 (-0.01%)

AMADY

Amadeus IT Group

$0.00

(0.00%)

NGLOY

Anglo American

$0.00

(0.00%)

BT

BT Group

$0.00

(0.00%)

CABGY

Carlsberg

$0.00

(0.00%)

WILYY

Demant

$0.00

(0.00%)

EONGY

E.ON

$0.00

(0.00%)

IKTSY

Intertek

$0.00

(0.00%)

NVS

Novartis

$93.00

-0.055 (-0.06%)

PSMMY

Persimmon

$0.00

(0.00%)

PUMSY

Puma

$0.00

(0.00%)

RSNAY

RSA Insurance

$0.00

(0.00%)

VOPKY

Koninklijke Vopak

$0.00

(0.00%)

HMSNF

Hammerson

$0.00

(0.00%)

NMHLY

NMC Health

$0.00

(0.00%)

RBGLY

Reckitt Benckiser

$0.00

(0.00%)

RNLSY

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 23

    Mar

AOBC

American Outdoor Brands

$9.23

-0.04 (-0.43%)

, AVCO

Avalon GloboCare

$2.27

-0.06 (-2.58%)

04:55
12/15/19
12/15
04:55
12/15/19
04:55
Conference/Events
Roth Capital to hold a conference »

8th Annual ROTH Deer…

AOBC

American Outdoor Brands

$9.23

-0.04 (-0.43%)

AVCO

Avalon GloboCare

$2.27

-0.06 (-2.58%)

BBSI

Barrett Business

$93.18

1.82 (1.99%)

BNGO

Bionano Genomics

$1.02

0.01 (0.99%)

IRMD

iRadimed

$25.25

-0.52 (-2.02%)

FC

Franklin Covey

$35.21

-0.57 (-1.59%)

NBEV

New Age Beverages

$1.91

-0.015 (-0.78%)

WATT

Energous

$1.99

(0.00%)

EAST

Eastside Distilling

$2.79

-0.12 (-4.12%)

DCTH

Delcath Systems

$0.00

(0.00%)

BOOM

DMC Global

$52.89

0.64 (1.22%)

CLAR

Clarus

$13.47

-0.02 (-0.15%)

JRSH

Jerash Holdings

$6.46

(0.00%)

MCHX

Marchex

$3.68

0.03 (0.82%)

JYNT

Joint Corp.

$17.37

0.28 (1.64%)

SOLY

Soliton

$10.35

-0.005 (-0.05%)

SMSI

Smith Micro

$4.66

0.095 (2.08%)

PWFL

PowerFleet

$6.10

0.05 (0.83%)

OSIS

OSI Systems

$100.60

0.63 (0.63%)

LOVE

Lovesac

$10.80

-1.01 (-8.55%)

VERI

Veritone

$2.73

-0.1 (-3.53%)

WTER

Alkaline Water

$1.09

-0.01 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 19

    Dec

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 29

    Jan

PNC

PNC Financial

$158.60

-0.3 (-0.19%)

, PYPL

PayPal

$107.68

2.01 (1.90%)

13:57
12/14/19
12/14
13:57
12/14/19
13:57
Periodicals
PNC clients having trouble connecting to PayPal's Venmo, WSJ reports »

Many of PNC…

PNC

PNC Financial

$158.60

-0.3 (-0.19%)

PYPL

PayPal

$107.68

2.01 (1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 15

    Jan

BRK.A

Berkshire Hathaway

$338,250.51

-992.49 (-0.29%)

, CMCSA

Comcast

$43.59

0.57 (1.33%)

07:44
12/14/19
12/14
07:44
12/14/19
07:44
Periodicals
Berkshire, Anthem among Barron's top 10 stock picks for 2020 »

Barron's has…

BRK.A

Berkshire Hathaway

$338,250.51

-992.49 (-0.29%)

CMCSA

Comcast

$43.59

0.57 (1.33%)

RDS.B

Royal Dutch Shell

$57.41

-0.19 (-0.33%)

RDS.A

Royal Dutch Shell

$57.44

-0.32 (-0.55%)

PFE

Pfizer

$38.31

-0.23 (-0.60%)

VIAC

ViacomCBS

$38.62

0.83 (2.20%)

ANTM

Anthem

$284.14

-0.405 (-0.14%)

DELL

Dell Technologies

$49.39

-0.11 (-0.22%)

GOOG

Alphabet

$1,348.07

-2.09 (-0.15%)

GOOGL

Alphabet Class A

$1,347.11

-1.4 (-0.10%)

UHAL

Amerco

$360.28

7.57 (2.15%)

UTX

United Technologies

$148.99

-0.5 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 27

    Feb

PCG

PG&E

$11.26

-0.49 (-4.17%)

07:38
12/14/19
12/14
07:38
12/14/19
07:38
Hot Stocks
California Governor says PG&E restructuring plan 'falls woefully short' »

California Governor Gavin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

MYGN

Myriad Genetics

$25.58

0.58 (2.32%)

07:31
12/14/19
12/14
07:31
12/14/19
07:31
Hot Stocks
Myriad Genetics says study validates polygenic risk score for breast cancer »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPC

Tutor Perini

$15.73

-0.17 (-1.07%)

07:30
12/14/19
12/14
07:30
12/14/19
07:30
Hot Stocks
Tutor Perini 'disappointed,' will appeal jury verdict in SR 99 Alaskan Way case »

Tutor Perini released a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLRX

BioLineRx

$2.38

-0.23 (-8.81%)

, BD

Budget Group

$0.00

(0.00%)

04:55
12/14/19
12/14
04:55
12/14/19
04:55
Conference/Events
European Society for Medical Oncology to hold a conference »

ESMO Immuno-Oncology…

BLRX

BioLineRx

$2.38

-0.23 (-8.81%)

BD

Budget Group

$0.00

(0.00%)

IDRA

Idera Pharmaceuticals

$1.59

-0.05 (-3.05%)

MRK

Merck

$89.18

0.84 (0.95%)

PFE

Pfizer

$38.31

-0.23 (-0.60%)

NKTR

Nektar

$21.28

-0.53 (-2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

ATNX

Athenex

$14.56

-2.38 (-14.05%)

, MRK

Merck

$89.18

0.84 (0.95%)

04:55
12/14/19
12/14
04:55
12/14/19
04:55
Conference/Events
Society of Surgical Oncology to hold a symposium »

San Antonio Breast Cancer…

ATNX

Athenex

$14.56

-2.38 (-14.05%)

MRK

Merck

$89.18

0.84 (0.95%)

ONCS

OncoSec

$2.00

-0.39 (-16.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

ACB

Aurora Cannabis

$2.63

0.02 (0.77%)

, CRON

Cronos Group

$7.28

-0.03 (-0.41%)

04:55
12/14/19
12/14
04:55
12/14/19
04:55
Conference/Events
MJBizDaily to hold a conference »

Marijuana Business…

ACB

Aurora Cannabis

$2.63

0.02 (0.77%)

CRON

Cronos Group

$7.28

-0.03 (-0.41%)

NFX

Newfield Exploration

$0.00

(0.00%)

CGC

Canopy Growth

$20.69

-0.455 (-2.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDSI

BioDelivery Sciences

$6.40

-0.065 (-1.01%)

04:55
12/14/19
12/14
04:55
12/14/19
04:55
Conference/Events
BioDelivery Sciences management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

AOBC

American Outdoor Brands

$9.23

-0.04 (-0.43%)

, AVCO

Avalon GloboCare

$2.27

-0.06 (-2.58%)

04:55
12/14/19
12/14
04:55
12/14/19
04:55
Conference/Events
Roth Capital to hold a conference »

8th Annual ROTH Deer…

AOBC

American Outdoor Brands

$9.23

-0.04 (-0.43%)

AVCO

Avalon GloboCare

$2.27

-0.06 (-2.58%)

BBSI

Barrett Business

$93.18

1.82 (1.99%)

BNGO

Bionano Genomics

$1.02

0.01 (0.99%)

IRMD

iRadimed

$25.25

-0.52 (-2.02%)

FC

Franklin Covey

$35.21

-0.57 (-1.59%)

NBEV

New Age Beverages

$1.91

-0.015 (-0.78%)

WATT

Energous

$1.99

(0.00%)

EAST

Eastside Distilling

$2.79

-0.12 (-4.12%)

DCTH

Delcath Systems

$0.00

(0.00%)

BOOM

DMC Global

$52.89

0.64 (1.22%)

CLAR

Clarus

$13.47

-0.02 (-0.15%)

JRSH

Jerash Holdings

$6.46

(0.00%)

MCHX

Marchex

$3.68

0.03 (0.82%)

JYNT

Joint Corp.

$17.37

0.28 (1.64%)

SOLY

Soliton

$10.35

-0.005 (-0.05%)

SMSI

Smith Micro

$4.66

0.095 (2.08%)

PWFL

PowerFleet

$6.10

0.05 (0.83%)

OSIS

OSI Systems

$100.60

0.63 (0.63%)

LOVE

Lovesac

$10.80

-1.01 (-8.55%)

VERI

Veritone

$2.73

-0.1 (-3.53%)

WTER

Alkaline Water

$1.09

-0.01 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 19

    Dec

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 29

    Jan

WFT

Weatherford

$0.00

(0.00%)

18:49
12/13/19
12/13
18:49
12/13/19
18:49
Hot Stocks
Weatherford completes financial restructuring, emerges from Chapter 11 »

Weatherford announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$57.71

-0.81 (-1.38%)

18:40
12/13/19
12/13
18:40
12/13/19
18:40
Hot Stocks
Centene CEO: Our big markets are growing, we're gaining share »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

LYV

Live Nation

$64.24

-5.205 (-7.50%)

, ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

18:29
12/13/19
12/13
18:29
12/13/19
18:29
Hot Stocks
S&P announces changes to S&P 400, 500, 600 indices »

S&P Dow Jones Indices…

LYV

Live Nation

$64.24

-5.205 (-7.50%)

ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

STE

Steris

$151.93

-1.745 (-1.14%)

AMG

Affiliated Managers

$85.18

-1.77 (-2.04%)

TRIP

TripAdvisor

$29.24

-0.2 (-0.68%)

MAC

Macerich

$26.04

-0.46 (-1.74%)

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

LEA

Lear

$129.43

-0.84 (-0.64%)

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

UNT

Unit Corp.

$0.83

-0.0626 (-6.98%)

FTR

Frontier Communications

$0.68

0.0315 (4.84%)

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

GVA

Granite Construction

$26.21

-1.335 (-4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 23

    Mar

PLAN

Anaplan

$51.80

1.44 (2.86%)

18:23
12/13/19
12/13
18:23
12/13/19
18:23
Hot Stocks
Anaplan CEO: Digitization has really started to accelerate »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPX

WPX Energy

$10.92

-0.24 (-2.15%)

18:08
12/13/19
12/13
18:08
12/13/19
18:08
Periodicals
WPX Energy in talks to acquire Felix Energy assets for $2.5B, Bloomberg says »

WPX Energy is in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

HLIT

Harmonic

$7.94

-0.25 (-3.05%)

17:47
12/13/19
12/13
17:47
12/13/19
17:47
Hot Stocks
Harmonic CFO sells 28K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$32.84

(0.00%)

17:36
12/13/19
12/13
17:36
12/13/19
17:36
Hot Stocks
Breaking Hot Stocks news story on Horizon Pharma »

Horizon Pharma up 9.6% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 08

    Mar

AMRN

Amarin

$24.12

1.12 (4.87%)

17:33
12/13/19
12/13
17:33
12/13/19
17:33
Hot Stocks
Breaking Hot Stocks news story on Amarin »

Amarin rises 1.4% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

THMO

ThermoGenesis

$2.88

(0.00%)

17:31
12/13/19
12/13
17:31
12/13/19
17:31
Syndicate
Breaking Syndicate news story on ThermoGenesis »

ThermoGenesis files $30M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

17:30
12/13/19
12/13
17:30
12/13/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Amarin 

Amarin trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

QTNT

Quotient

$8.60

-0.165 (-1.88%)

17:28
12/13/19
12/13
17:28
12/13/19
17:28
Syndicate
Breaking Syndicate news story on Quotient »

Quotient files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

, GVA

Granite Construction

$26.21

-1.335 (-4.85%)

17:27
12/13/19
12/13
17:27
12/13/19
17:27
Hot Stocks
Breaking Hot Stocks news story on Arrowhead, Granite Construction »

Arrowhead to replace…

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

GVA

Granite Construction

$26.21

-1.335 (-4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

, SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

17:25
12/13/19
12/13
17:25
12/13/19
17:25
Hot Stocks
Oasis, Southwestern to replace Unit Corp., Frontier in S&P 600 at open on 12/23 »

Oasis Petroleum (OAS) and…

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

UNT

Unit Corp.

$0.83

-0.0626 (-6.98%)

FTR

Frontier Communications

$0.68

0.0315 (4.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.